. . "Estramustine"@en . "Estramustina"@en . . . . . . . "approved"@en . . " "@en . . "20 hours"@en . "For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate"@en . . . . . . . "17\u03B2-Estradiol 3-(bis(2-chloroethyl)carbamate)"@en . . . . . . . . . . . . "A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties. [PubChem]"@en . . "Estradiol 3-(N,N-bis(2-chloroethyl)carbamate)"@en . . . . "The metabolic urinary patterns of the estradiol moiety of estramustine phosphate and estradiol itself are very similar, although the metabolites derived from estramustine phosphate are excreted at a slower rate."@en . . "Do not take with milk or milk products."@en . . "17beta-Estradiol 3-(bis(2-chloroethyl)carbamate)"@en . . "Humans and other mammals"@en . "Fex, H.J., Hogtierg, K.B., Konyves, I. and Kneip, P.H.0.L; U.S. Patent 3,299,104; Jan. 17, 1967; assigned to Leo AB, Sweden."@en . . "2998-57-4"@en . . "Estramustine is a derivative of estradiol with a nitrogen mustard moiety. This gives it alkylating properties. In vivo, the nitrogen mustard component is active and can alklyate DNA and other cellular components (such as tubulin components) of rapidly dividing cells. This causes DNA strandbreaks or misscoding events. This leads to apoptosis and cell death. Also, due to the drugs estrogen component, it can bind more selectively to active estrogen receptors."@en . . "Estramustinum"@en . . . . "Estramustine"@en . . . " "@en . . . . "Take on an empty stomach."@en . . . . .